Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment LoomsInvestors Business Daily • 11/04/24
Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock24/7 Wall Street • 10/31/24
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 10/30/24
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week CongressBusiness Wire • 10/25/24
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market AwaitsThe Motley Fool • 10/24/24
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingBusiness Wire • 10/18/24
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 10/14/24
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?Zacks Investment Research • 09/26/24
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceBusiness Wire • 09/26/24